1 Calvisi DF, "Ubiquitous activation of Ras and Jak/Stat pathways in human HCC" 130 : 1117-1128, 2006
2 Verstovsek S., "Therapeutic potential of JAK2 inhibitors" 636-642, 2009
3 Yu H, "The STATs of cancer : new molecular targets come of age" 4 : 97-105, 2004
4 Sansone P, "Targeting the interleukin-6/Jak/stat pathway in human malignancies" 30 : 1005-1014, 2012
5 Alvarez JV, "Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor" 66 : 3162-3168, 2006
6 Mizutani Y, "Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum(II)by anti-interleukin 6monoclonal antibody or anti-interleukin 6 receptor monoclonal antibody" 55 : 590-596, 1995
7 Yu H, "STATs in cancer inflammation and immunity : a leading role for STAT3" 9 : 798-809, 2009
8 Lin L, "STAT3 is necessary for proliferation and survival in colon cancer-initiating cells" 71 : 7226-7237, 2011
9 Morikawa T, "STAT3 expression, molecular features, inflammation patterns, and prognosis in a database of 724 colorectal cancers" 17 : 1452-1462, 2011
10 Levy DE, "STAT3 : a multifaceted oncogene" 103 : 10151-10152, 2006
1 Calvisi DF, "Ubiquitous activation of Ras and Jak/Stat pathways in human HCC" 130 : 1117-1128, 2006
2 Verstovsek S., "Therapeutic potential of JAK2 inhibitors" 636-642, 2009
3 Yu H, "The STATs of cancer : new molecular targets come of age" 4 : 97-105, 2004
4 Sansone P, "Targeting the interleukin-6/Jak/stat pathway in human malignancies" 30 : 1005-1014, 2012
5 Alvarez JV, "Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor" 66 : 3162-3168, 2006
6 Mizutani Y, "Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum(II)by anti-interleukin 6monoclonal antibody or anti-interleukin 6 receptor monoclonal antibody" 55 : 590-596, 1995
7 Yu H, "STATs in cancer inflammation and immunity : a leading role for STAT3" 9 : 798-809, 2009
8 Lin L, "STAT3 is necessary for proliferation and survival in colon cancer-initiating cells" 71 : 7226-7237, 2011
9 Morikawa T, "STAT3 expression, molecular features, inflammation patterns, and prognosis in a database of 724 colorectal cancers" 17 : 1452-1462, 2011
10 Levy DE, "STAT3 : a multifaceted oncogene" 103 : 10151-10152, 2006
11 Deng JY, "STAT-3 correlates with lymph node metastasis and cell survival in gastric cancer" 16 : 5380-5387, 2010
12 Jove R, "Preface : STAT signaling" 19 : 2466-2467, 2000
13 Bendell JC, "Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors" 74 : 125-130, 2014
14 Kim MJ, "OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells" 335 : 145-152, 2013
15 Motte N, "Mutations in JAK2V617F homologous domain of JAK genes are uncommon in solid tumors" 121 : 2113-2115, 2007
16 Li WC, "Inhibition of growth and metastasis of human hepatocellular carcinoma by antisense oligonucleotide targeting signal transducer and activator of transcription 3" 12 : 7140-7148, 2006
17 Alas S, "Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis" 9 : 316-326, 2003
18 Chen J, "Inhibition of STAT3 signaling pathway by nitidine chloride suppressed the angiogenesis and growth of human gastric cancer" 11 : 277-287, 2012
19 Mankan AK, "Inhibiting signal transducer and activator of transcription 3 : rationality and rationale design of inhibitors" 20 : 1263-1275, 2011
20 Gong W, "Expression of activated signal transducer and activator of transcription 3 predicts expression of vascular endothelial growth factor in and angiogenic phenotype of human gastric cancer" 11 : 1386-1393, 2005
21 Grandis JR, "Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo" 97 : 4227-4232, 2000
22 Levine RL, "Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis" 7 : 387-397, 2005
23 Baxter EJ, "Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders" 365 : 1054-1061, 2005
24 James C, "A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera" 434 : 1144-1148, 2005
25 Kralovics R, "A gain-of-function mutation of JAK2 in myeloproliferative disorders" 352 : 1779-1790, 2005